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Iron in diet 
Recombinant human erythropoietin 
(rHuEPO) is widely used to treat the 
anaemia associated with chronic renal fail-
ure. Many physicians are unsure of the 
role of iron in the treatment of this condi-
tion and therefore fail to achieve the opti-
mum response to rHuEPO. A roundtable 
meeting of European experts was held to 
discuss issues relating to iron management, 
with the aim of producing guidelines 
on assessment and treatment of chronie 
renal failure for nephrologists and 
haematologists. 
Iron status before rHuEPO treatment 
Patients considered for rHuEPO treatment are 
likely to have been identified from their low 
haemoglobin (Hb) concentrations, but it is also 
important to consider their iron status to assess 
their need for supplementary iron. 
The normal distribution of body iron and path-
ways of iron metabolism are shown in Figure 1. 
Patients with chronic renal failure may have Hb 
concentrations as low as 6 g/dl (normal range, 
12-18 g/dl). Each rise of 1 g/dl in the circulating 
Hb requires approximately 150 mg of storage 
iron l which is equivalent to a serum ferritin 
concentration of about 20 ~g/1. To increase a 
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patient's Hb concentration from 6 to 12 g/dl will 
require iron stores equivalent to a serum ferritin 
concentration of at least 120 ~g/1. 
Before rHuEPO treatment has begun ferritin 
levels will provide a measure of storage iron. 
Patients with serum ferritin concentrations below 
15 ~g!l have virtually no available iron and are 
unlikely to respond weil to rHuEPO without iron 
supplementation. Even where serum ferritin con-
centrations are up to 200 ~g/I, iron supplementa-
tion may still improve the patient's response 
to rHuEPO. If serum ferritin levels are over 
200 ~g!l, extra iron is probably unnecessary 
(Figure 2). 
Iron status during rHuEPO treatment 
Correction phase 
Once rHuEPO treatment has begun, serum fer-
ritin levels may become a less reliable measure of 
iron stores, since ferritin concentrations are 
affected by the rHuEPO treatment itself and also 
by treatment with intravenous (IV) iron. For this 
reason, measurement of ferritin concentrations 
should be performed at least 2-3 weeks afier the 
end of IV iron therapy. 
The most direct method of assessing the iron 
available to erythroid tissue is the measurement 
of the red cell Hb concentration by flow 
cytometry. Functional iron deficiency (see below) 
may be diagnosed when more than 10% of 
the circulating red cells are hypochromic - that 
is, have an individual cell Hb concentration 
below 28 g/ dl. 
The ability to assess the proportion of 
hypochromic red cells as part of the full blood 
count is an important tool in managing rHuEPO-
treated patients. However, not aIl centres current-
Iy have access to the automated blood cell analy-
sers that can perform this measurement, and 
many physicians are therefore required to use 
other methods for measuring iron status during 
rHuEPO treatment. 
Several indirect techniques have been pro-
posed, but none is as reliable as direct measure-
ment of red cell hypochromia. Transferrin levels 
fluctuate widely both within and between indi-
viduals, and single measurements are not useful 
during rHuEPO treatment, although repeated 
measurements may provide more information. 
Patients with a transferrin saturation con-
sistently below 20% are likely to be experiencing 
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functional iron deficiency. However, where 
levels are above 20%, this diagnosis still should 
not be ruled out. Transferrin receptor levels 
reflect erythropoietic activity rather than iron 
status during this phase of therapy and do 
not provide a useful measurement of functional 
iron deficiency. 
Maintetmnce phase 
Once steady-state erythropoiesis is achieved, mea-
surements of serum ferritin may once again 
reflect a patient's levels of storage Iron. Similarly, 
measurements of transferrin receptor concentra-
tions could prove useful. Receptor synthesis is 
likely to be increased under conditions of inade-
quate Iron supply to the marrow; its exact role, 
however, has yet to be defined. 
Functional iron deficiency -
definition and effects 
Erythropoietin treatment places extreme demands 





concentration may be limited by the rate at which Figure 2. Assessing iron status at the start of rHuEPO treatment 
iron can be supplied to the developing erythro-
cyte progenitor pool in the bone marrow. 
Functional iron deficiency develops when iron 
supplies are insufficient to meet demand. Iron-
deficient erythropoiesis can occur despite the 
presence of apparently adequate iron stores as 
judged by serum ferritin levels. Even patients 
with serum ferritin concentrations above 100 ~g/I 
will frequently exhibit functional iron deficiency. ' , ~ 
The development of functional iron deficiency ............... _ 
rnay depend on the speed of erythroid expansion, -
although it may be evident even with low doses 
ofrHuEPO. 
Patients with lunctional iron deficiency are 
likely to show a poor response to rHuEPO (Figure 
3), and the availability of iron probably influ-
ences the dose-response curve of rHuEPO. Thus, 
maintenance of an adequate iron supply may 
reduce rHuEPO requirements, and the same rise 
in Hb concentration may be achieved with a 
lower dose of rHuEPO. 
Choice of iron treatment 
Preventing iron deficiency during rHuEPO thera-
py will increase the cost-effectiveness of treat-
ment. There is increasing evidence that patients 
who receive more frequent IV Iron treatment 
require lower doses of rHuEPO. Decisions about 
the best dosage, formulation and delivery route 
of Iron will depend on practical considerations. 
These decisions will also be influenced by 
the availability of different forrns of iron 
supplementation in different countries. 
IViron 
Various IV iron formulations are available 
for treating patients receiving rHuEPO - iron Figure 3. Guidelines for iron management during rHuEPO treatment 
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Therapeutics 
dextran is used in North America, iron dextran 
(polymaltose) and hydroxysaccharate are avail-
able in continental Europe and Iron sodium 
gluconate has been used occasionally. The major 
disadvantage of Iron dextran is the occasional 
development of acute anaphylactic reactions. A 
test dose should be administered initially, and 
resuscitation facilities should always be available 
during its use. Less life-threatening, but nonethe-
Patients 
less problematic, side-effects of IV Iron dex-
tran include arthralgia and myalgia, but 
these may be avoided by using low repeated 
doses. Small-weight molecules such as Iron 
sodium gluconate may cause problems of 




treated with Patients receiving haemodialysis in hospi-
tal are best treated with repeated small doses 
of IV Iron. Decisions regarding frequency 
and dose will depend on the individual 
clinician. A typical dose would be 100-300 
repeated 
small doses 
of IV iron 
mg in the last 1-2 hours of up to ten weekly or 
fortnightly dialysis sessions. 
For patients attending hospital less frequently 
and those without IV access, such as predialysis 
and CAPD patients, a much larger loading dose of 
IV Iron (1 g) may be given at a single session, but 
this could increase the risk of adverse reactions. 
At the start of rHuEPO treatment and 
during the correction phase, IV iTon is more 
effective than oral Iron. This may be because 
chronic renal failuTe, chronic inflammation and 
rHuEPO treatment itself may affect the absorp-
tion of oral iTon. 
However, IV Iron should be used with 
caution in patients with a bacterial infection, 
since it may encourage bacterial growth. 
Oraliron 
During the maintenance phase, oral Iron may be 
sufficient to achieve an adequate Iron supply. 
However, preparations providing the most readily 
absorbable Iron are also most likely to cause gas-
trointestinal side-effects. Thus the dose and 
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formulation may need to be adjusted to achieve a 
regimen that is acceptable to the patient and is 
least likely to reduce compliance. Most patients 
should start with ferrous sulphate 200 mg tid, 30 
minutes before meals. If this is not well tolerated 
they should be advised to take the Iron tablets 
afler meals. 
If side-effects persist, reducing the frequency 
or lowering the dose of ferrous sulphate should 
be tried. If this is still unacceptable, patients may 
try other ferrous compounds that contain less 
elemental Iron in each tablet. 
Other causes ofhyporesponsiveness 
While Iron supplementation may be the key 
to optimising rHuEPO therapy in the great 
majority of patients receiving treatment for 
anaemia of renal origin, a small proportion of 
patients may have a poor response to rHuEPO for 
other reasons. 
Poor response may be due to infection, inflam-
matory disease, malignancy, blood loss, hyper-
parathyroidism, aluminium overload (causing a 
functional deficiency that is unresponsive to 
extra Iron) or haemolysis. The assessment of 
Iron status may also be affected by sorne of 
these factors. 
Optbnising therapeutic efficacy 
Serum ferritin should be measured before 
rHuEPO treatment and any storage Iron deficien-
cy treated, preferably with IV iron. During 
rHuEPO treatment, functional Iron deficiency 
should be monitored by measuring the percent-
age of hypochromic red cells. This parameter 
is an important tool in the management of 
rHuEPO-treated patients and should be more 
widely available. When this information is not 
available, repeated measures of serum ferritin 
concentrations are an unreliable substitute. Iron 
supplementation should be introduced during 
the correction phase. 
Good maintenance of Iron status in patients 
receiving long-term rHuEPO treatment will 
optimise therapeutic efficacy and may permit 
cost savings • 
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